#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acquired haemophilia Hepatocellular carcinoma Fallopian tube cancer Adrenoleukodystrophy Ependymoma Splenic marginal zone lymphoma X-linked lymphoproliferative syndrome Neurodegenerative disorder Anti-myelin-associated glycoprotein antibodies positive Retinitis pigmentosa Oesophageal squamous cell carcinoma stage II Antiphospholipid syndrome Hodgkin's disease recurrent Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Soft tissue sarcoma More trials…

    Learn about Rare Diseases

    Glycogen storage disease type I – Life with Disease Leiomyosarcoma recurrent IgA nephropathy – Treatment Glomerulonephritis membranoproliferative Hypereosinophilic syndrome – Basic Information Niemann-Pick disease – Trials in Disease Niemann-Pick disease – Life with Disease Behcet’s syndrome – Basic Information Nodal marginal zone B-cell lymphoma Bronchiolitis obliterans syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    RNK001 Hmb-001 Ligelizumab Pimecrolimus GSKVX000000048110 Chloropyramine Hydrochloride TX000045 Tozorakimab [Al[18F]F]Fapi-74 Sonelokimab Lutetium (177Lu)-Neobomb1 Naloxone Ergocalciferol Bp Ivabradine 177LU-FAP-2286 Zelicapavir APROTININ 4-Hydroxy-N-Desmethyltamoxifen Atrasentan Hydrochloride Florquinitau (18F) More therapies…

    Learn about Your Condition

    Autoimmune disorder Primary adrenal insufficiency Cleft lip and palate Radiation skin injury Tetanus Endometrial cancer stage III Gout Thrombosis prophylaxis Pneumonia bacterial Iron deficiency Pericarditis Carotid arteriosclerosis Paedophilia Vulvovaginal pain Procedural headache More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Parc Tauli Hospital Universitari

Parc Tauli Hospital Universitari

Parc Del Tauli 1, Sabadell, 08208, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Darolutamide
    Belgium Bulgaria Czechia Estonia Finland France +11

  • Study on Secukinumab and Prednisone for Patients with Polymyalgia Rheumatica Who Have Recently Relapsed

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Secukinumab
    • Prednisone
    Belgium Czechia Denmark Finland France Germany +9

  • Study on Volixibat for Treating Itching in Patients with Primary Biliary Cholangitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Primary biliary cholangitis
    Investigated Drugs:
    • Volixibat
    Belgium France Germany Italy The Netherlands Spain

  • Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Atrial fibrillation
    Investigated Drugs:
    • Andexanet Alfa
    • Milvexian
    • Apixaban
    Belgium Bulgaria Croatia Czechia Denmark Estonia +13

  • Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients

    Not recruiting

    3 1
    Investigated Drugs:
    • Rifaximin
    Belgium Bulgaria France Germany Hungary Italy +2

  • Study on the Long-Term Safety and Effectiveness of Amlitelimab for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Amlitelimab
    Czechia Denmark France Germany Italy The Netherlands +2

  • Study of FOLFOX6m, Bevacizumab, and Irinotecan for Patients with Colorectal Cancer and Liver Metastases

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Panitumumab
    • Bevacizumab
    • Cetuximab
    Spain

  • Study on the Safety and Tolerability of Rugonersen in Patients with Angelman Syndrome

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Angelman’s syndrome
    Investigated Drugs:
    • Rugonersen
    Italy The Netherlands Spain

  • Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Tivozanib
    • Nivolumab
    Belgium Czechia France Germany Italy Poland +2

  • Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Cystic fibrosis
    Investigated Drugs:
    • Elexacaftor
    • Tezacaftor
    • Ivacaftor
    Austria Belgium Czechia France Germany Hungary +7
Previous Page
1 … 25 26 27 28 29
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!